Icon

TRILEPTAL (nda021014)- (150MG,300MG,600MG)

OXCARBAZEPINE NOVARTIS
150MG,300MG,600MG
Yes No
2018-Aug-12 Expired
None None
None No
TRILEPTAL is indicated for:  Adults: Monotherapy or adjunctive therapy in the treatment of partial-onset seizures  Pediatrics: - Monotherapy in the treatment of partial-onset seizures in children 4–16 years - Adjunctive therapy in the treatment of partial-onset seizures in children 2–16 years.
8 0 6
Total Other Developers 5
Drugs with Suitability No
150MG ** ** - - 5
300MG ** ** Up - 5
600MG ** ** Up 4 1
NDA Sales Available Total Generic Sales Available
Yes 5
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country
****** ******* ******* ******** ******* ******* *********** **** ** *-**/* & ***/*, ****, ********** ********* ****,, *****, *********** *** ***, ***** (***) ***
****** *** ***** **** *** ************** ********** ******* *********** *****-****** *******, *****, ******* ******, ***** (***) ***
****** **** **** ************** ********** ***. *********** ** ******* ******, ***** ***, *******, ****** (***) ***
****** ******** ****** *** ******** *************** ******* *********** **** **. *, *****-*, ****** **** *** *********, ****, ****** ******* ******, ***** (***) ***
****** ******** ****** *** ******** *************** ******* *********** **** ** *-*, ******* ********** ******, *******-******,, ***, ** ******, ***** (***) ***
****** ************ ***** *** ****** *********, *** *********** ***** ******** ******, ******, ********** (**) *****, ****** ****** (***) ***
****** ************ ***** **** ************** ******, *.*. *********** ***** ** **** *****, **-**, ***********, *****, ***** (***) ***
****** ****** ****** ****** ****** ******* ******* *********** ****** **. ***, ******* *******, *********** ******,, **********, ********* ******, ***** (***) ***

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search





Expired
to
Expired
to


Please contact contact@researchdelta.com to get more details.